Healthcare / Diagnostics & ResearchBSE
$72.50
+2.51 (+3.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $98.9M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
6.6x
↓EV/EBITDA
2.8x
↓ROE
16.6%
↑Gross Margin
56.1%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+14.7%
FCF CAGR
—
FCF margin
14.8%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $885.3M · net income $192.8M · FCF $130.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $885.3M | $885.3M | $835.0M | $799.7M | $586.8M |
| Net Income | $192.8M | $192.8M | $159.3M | $124.2M | $5.8M |
| EBITDA | $341.6M | $341.6M | $288.9M | $235.5M | $59.7M |
| EPS | — | — | 9.14 | 7.13 | 0.33 |
| Gross Margin | 56.1% | 56.1% | 53.9% | 46.1% | 35.0% |
| Operating Margin | 33.0% | 33.0% | 28.3% | 22.6% | 3.7% |
| Net Margin | 21.8% | 21.8% | 19.1% | 15.5% | 1.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.69 | 0.98 | 1.40 |
| Current Ratio | 4.00 | 4.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $130.9M | $130.9M | $-68.5M | $98.9M | $-20.3M |
| Returns | |||||
| ROE | 16.6% | 16.6% | 33.8% | 39.6% | 3.1% |
| Valuation | |||||
| P/E | 6.56 | 6.56 | — | — | — |
| EV/EBITDA | 2.79 | 2.79 | — | — | — |
| P/B | 1.09 | 1.09 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 6.0% | 6.0% | 4.4% | 36.3% | — |
| EPS Growth | — | — | 28.3% | 2045.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.7%
Start / end P/E
n/dx → n/dx
EPS bridge
9.14 → n/d
Residual
-46.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.